Renal function and thromboprophylaxis in critically ill patients by Scholey, Gareth M et al.
Robinson and colleagues [1] recently examined the eﬀ  ec-
tive dose of enoxaparin for thromboprophylaxis in 
critically ill patients recorded over 24 hours. Th  e study 
concluded that the standard dose of 40 mg led to sub-
therapeutic anti-factor Xa activity (aFXa) and 60 mg daily 
was optimal. Th  e high rate of thromboembolic disease 
observed in critically ill patients could thus be explained 
by inadequate aFXa with the standard 40 mg dose.
Low molecular weight heparins (LMWHs) are renally 
excreted and Robinson and colleagues excluded patients 
receiving renal replacement therapy as this may have 
inﬂ   uenced aFXa [1]. Douketis and colleagues [2] 
documented that excessive anticoagulation did not occur 
with prophylactic doses of dalteparin in critically ill 
patients with severe renal impairment. However, in a 
study of two diﬀ  erent prophylactic LMWHs in elderly 
patients with impaired renal function, enoxaparin but 
not tinzaparin accumulated over 8 days [3]. Th  e  pharma-
co  kinetics of diﬀ  erent LMWHs varies [3,4], and excessive 
anticoagulation over time might occur with a 60 mg daily 
dose of enoxaparin, especially if renal function is 
impaired.
Perturbations of renal function may also explain why 
standard dose enoxaparin is subtherapeutic in many 
critically ill patients [1]. Fuster-Lluch and colleagues [5] 
reported that 30% of patients show augmented renal 
clearance during the ﬁ  rst week of critical illness. Typically, 
those with supranormal creatinine clearance were post-
operative patients or had sepsis or trauma. Th  is patient 
group is hypercoagulable and at high risk of thrombo-
embolic disease; however, augmented renal clearance 
would reduce the eﬀ  ectiveness of LMWHs. Th  e optimal 
prophylactic dose of LMWHs in critical illness is probably, 
therefore, best determined by monitoring of aFXa.
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We thank Dr Scholey and colleagues for the careful 
reading of our paper, and agree that the problem of 
prophylactic anticoagulation in this patient population is 
a complex one. Whilst our study seems to support the 
theory of inadequate dosage being a possible mechanism 
for the higher failure rate of enoxaparin in ICU patients, 
we acknowledge that there may be other possible 
mechanisms at play. Scholey and colleagues point to 
augmented renal function in particular, while still other 
researchers have implicated the presence of multiple 
organ dysfunction syndrome, obesity, and the use of 
vasopressors as likely culprits [6].
Conversely, Dr Scholey and colleagues note that renal 
impairment may lead to the bioaccumulation of a 60 mg 
dose of enoxaparin. In fact, renal impairment may lead to 
enoxaparin accumulation at standard doses [7], and most 
authorities advocate avoidance of LMWHs in this patient 
population [8]. Such patients were thus excluded from 
our study. However, patients with renal impairment do 
account for a sizeable portion of ICU clientele, and it is 
incongruous to attempt the establishment of guidelines 
for the use of LMWH prophylaxis in ICU patients, whilst 
continuing to exclude this important subgroup.
aFXa is only a surrogate parameter, one that has never 
been conclusively shown to be directly related to clinical 
outcome [9,10]. We are currently at the design phase in a 
study intended to determine whether the improved aFXa 
levels associated with 60 mg enoxaparin will translate 
into fewer venous thromboembolic events without the 
concomitant risk of increased bleeding episodes.
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